Page last updated: 2024-10-31

mianserin and Dermatitis, Exfoliative

mianserin has been researched along with Dermatitis, Exfoliative in 1 studies

Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.

Dermatitis, Exfoliative: The widespread involvement of the skin by a scaly, erythematous dermatitis occurring either as a secondary or reactive process to an underlying cutaneous disorder (e.g., atopic dermatitis, psoriasis, etc.), or as a primary or idiopathic disease. It is often associated with the loss of hair and nails, hyperkeratosis of the palms and soles, and pruritus. (From Dorland, 27th ed)

Research Excerpts

ExcerptRelevanceReference
"In cases of malignancy that are refractive to treatment, other therapies have been found to be effective for paraneoplastic itch, including selective serotonin reuptake inhibitors, mirtazapine, gabapentin, thalidomide, opioids, aprepitant, and histone deacetylase inhibitors."2.53Paraneoplastic Itch Management. ( Rowe, B; Yosipovitch, G, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Rowe, B1
Yosipovitch, G1

Reviews

1 review available for mianserin and Dermatitis, Exfoliative

ArticleYear
Paraneoplastic Itch Management.
    Current problems in dermatology, 2016, Volume: 50

    Topics: Acantholysis; Acanthosis Nigricans; Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Apre

2016